Research Day Speaker


Research Day Speaker

Main Content

The College of Pharmacy is pleased to present Dr. Adeboye Adejare, PhD, Professor of Pharmaceutical Sciences, University of the Sciences, as the 2022 Research Day keynote speaker.

March 31, 2022
11:45 a.m. 
BRT 115

AdejareProfessor Adeboye Adejare received a Bachelor of Science in 1978 and Master’s of Science in 1980 in Chemistry from The University of Iowa followed by a PhD in Medicinal Chemistry from The Ohio State University in 1985. He completed postdoctoral studies at the National Institutes of Health (NIH) prior to beginning career in academia. Professor Adejare is currently a professor of Pharmaceutical Sciences at the Philadelphia College of Pharmacy and a research professor of Chemistry at University of the Sciences in Philadelphia.

His research is geared towards discovery of novel compounds that can be used to probe mechanisms of, and for treatment of neurodegeneration as observed in Alzheimer’s disease and related disorders, anti-cancer drug discovery, and pharmaceutical profiling. Professor Adejare’s research was/is funded by several agencies including the NIH and several pharmaceutical companies. These efforts have resulted in over 50 publications, 5 patents and over 100 major meeting presentations. Several graduates from his group are employed in academia and the pharmaceutical industry. Dr. Adejare served/serves on several national panels, including grant review panels for NIH, NSF, National Academy of Science, and Alzheimer’s Association. He is the Editor-in-Chief of Remington: The Science and Practice of Pharmacy. He is also editor of “Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease”.

Seminar Abstract: 

"Rethinking CNS Drug Discovery"
There are many new developments in CNS drug discovery, from FDA approvals of Aducanumab for treatment of Alzheimer’s disease (AD) to Ketamine for treatment-resistant depression. The demand for CNS drugs are increasing, for instance, there is high demand for non-opioid drugs for the treatment of pain and those for treating addiction. In the meantime, many pharmaceutical companies are pulling out of CNS drug discovery, in part due to the high failure rates in clinical trials. Using developments in the NMDA receptors area for treatment of AD as well as other areas for illustrations, the talk will focus on what might be new strategies for CNS drug discovery, from polypharmacology to pharmacognosy.